Markets:

Overview

News

Currencies

International

Treasuries

Restart Life Sciences Cp (OP:NMLSF)

0.0970 +0.0143 (+17.29%)

Streaming Delayed Price Updated: 10:05 AM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Restart Life Sciences Cp

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism ↗

April 20, 2023

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <

Via Benzinga

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗

February 21, 2023

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...

Via Benzinga

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder ↗

February 14, 2023

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a...

Via Benzinga

Nova Mentis Is Looking To Treat Autism With Psilocybin ↗

April 07, 2022

Nova Mentis Life Science Corp. (OTCQB: NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a ...

Via Benzinga

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval ↗

December 27, 2022

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a...

Via Benzinga

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project ↗

December 06, 2022

Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...

Via Benzinga

Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial ↗

November 30, 2022

Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc.

Via Benzinga

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial ↗

November 17, 2022

Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science...

Via Benzinga

Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin ↗

September 30, 2022

Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops

Via Benzinga

Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn ↗

September 29, 2022

Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry,...

Via Benzinga

New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details ↗

September 17, 2022

Canadian-based psychedelics company Nova Mentis Life Science Corp.

Via Benzinga

More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases ↗

June 16, 2022

The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB: NMLSF) is filing new provisional patent applications to the U.S.

Via Benzinga

Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies ↗

June 08, 2022

The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs.

Via Benzinga

Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened ↗

June 07, 2022

Nova Mentis Life Science Corp. (OTCQB: NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently...

Via Benzinga

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study ↗

February 22, 2022

Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. ...

Via Benzinga

This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism ↗

February 16, 2022

Nova Mentis Life Science Corp (OTCQB: NMLSF) is a biotechnology company focused on psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. The...

Via Benzinga

Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market ↗

February 08, 2022

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis ↗

January 27, 2022

The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada

Via Benzinga

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval ↗

November 08, 2021

Detroit Decriminalizes Psychedelics

Via Benzinga

Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent ↗

October 26, 2021

The Week In Psychedelics

Via Benzinga

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Restart Life Sciences Cp (OP:NMLSF)

Headline News about Restart Life Sciences Cp

Starting at $3.75/week.

Subscribe Today